BMSSC
MRTX

B. Metzler seel. Sohn & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,302
Closed -$436K – 781
2022
Q1 		$436K Buy
+5,302
New +$542K 0.01% 626

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

B. Metzler seel. Sohn & Co's MRTX Position: Q2 2022 in Review

B. Metzler seel. Sohn & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 5,302 shares — an estimated $436K sold.

B. Metzler seel. Sohn & Co first reported a position in MRTX in Q1 2022 and held it in 1 quarter. The position peaked at $436K in Q1 2022. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • B. Metzler seel. Sohn & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 5,302 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $436K.
  • B. Metzler seel. Sohn & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • B. Metzler seel. Sohn & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $436K in Q1 2022.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2022, filed 12 Aug 2022.